Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Excepgen Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, providing two different points of contact at the USPTO. Furthermore, the actions are located in 2 distinct art units, which suggests that the company's technology is being examined by two different specialized groups. This distribution means that the company cannot rely on a single set of examiner behaviors or art unit norms.
The busiest examiner, ALLEN, MICHAEL D, is handling 1 busiest examiner pending action. This accounts for one of the 2 pending office actions currently facing the company. Having 2 distinct examiners across 2 distinct art units requires the Biotechnology & Pharmaceuticals strategy to be adaptable to different departmental requirements. Practitioners should be prepared for potentially different outcomes or timelines for the 2 pending office actions, as they are being processed by different individuals in different specialized units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18465335 | SYSTEMS AND METHODS FOR PROTEIN EXPRESSION | ZARA, JANE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18466251 | VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | ALLEN, MICHAEL D | — |
| 18465335 | SYSTEMS AND METHODS FOR PROTEIN EXPRESSION | ZARA, JANE J | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18466251 | VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | ALLEN, MICHAEL D | 1671 | §112 | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18465335 | SYSTEMS AND METHODS FOR PROTEIN EXPRESSION | ZARA, JANE J | 1637 | §102§112 | Non-Final OA | — | Pending | Sep 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial